The global Drugs for Duchenne Muscular Dystrophy (DMD) market size was estimated at USD 198 million in 2024 and is projected to reach USD 514.76 million by 2032, exhibiting a CAGR of 11.20% during the forecast period.
North America Drugs for Duchenne Muscular Dystrophy (DMD) market size was estimated at USD 61.97 million in 2024, at a CAGR of 9.60% during the forecast period of 2025 through 2032.
Report Overview
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchennea mutation in the DMD genehappens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
This report provides a deep insight into the global Drugs for Duchenne Muscular Dystrophy (DMD) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Drugs for Duchenne Muscular Dystrophy (DMD) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Drugs for Duchenne Muscular Dystrophy (DMD) market in any manner.
Global Drugs for Duchenne Muscular Dystrophy (DMD) Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Sarepta Therapeutics
- PTC Therapeutics
- Pfizer
- Bristol-Myers Squibb
- Italfarmaco
- Santhera Pharmaceuticals
- WaVe life Science
Market Segmentation (by Type)
- Eteplirsen
- Deflazacort
- Ataluren
Market Segmentation (by Application)
- Hospitals
- Clinics
- Home Care
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
FAQs on the Global Drugs for Duchenne Muscular Dystrophy (DMD) Market (2024–2032)
Q1: What is the market size of the Drugs for Duchenne Muscular Dystrophy (DMD) market in 2024?
A: The global Drugs for DMD market was valued at approximately USD 198 million in 2024.
Q2: What is the projected market size for Drugs for Duchenne Muscular Dystrophy by 2032?
A: The market is expected to grow to around USD 514.76 million by 2032.
Q3: What is the CAGR of the Drugs for DMD market during the forecast period?
A: The market is forecasted to grow at a Compound Annual Growth Rate (CAGR) of 11.20% from 2024 to 2032.
Q4: What types of drugs are included in the Duchenne Muscular Dystrophy treatment market?
A: This market includes:
Q5: What factors are driving the growth of the Drugs for DMD market?
A: Growth is driven by:
-
Increasing prevalence and awareness of Duchenne Muscular Dystrophy
-
Advances in gene therapy and molecular medicines
-
Expanding pipeline of novel DMD drugs
-
Rising healthcare infrastructure and funding for rare diseases
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Drugs for Duchenne Muscular Dystrophy (DMD) Market
- Overview of the regional outlook of the Drugs for Duchenne Muscular Dystrophy (DMD) Market:
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porters five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
Customization of the Report
- In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
- Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
- Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Drugs for Duchenne Muscular Dystrophy (DMD) Market and its likely evolution in the short to mid-term, and long term.
- Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
- Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
- Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
- Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
- Chapter 9 shares the main producing countries of Drugs for Duchenne Muscular Dystrophy (DMD), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
- Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
- Chapter 11 provides a quantitative analysis of the market size and development potential of each region during the forecast period.
- Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.
- Chapter 13 is the main points and conclusions of the report.
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Drugs for Duchenne Muscular Dystrophy (DMD)
1.2 Key Market Segments
1.2.1 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Type
1.2.2 Drugs for Duchenne Muscular Dystrophy (DMD) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Drugs for Duchenne Muscular Dystrophy (DMD) Market Overview
2.1 Global Market Overview
2.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Competitive Landscape
3.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Manufacturers (2019-2025)
3.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Manufacturers (2019-2025)
3.3 Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Drugs for Duchenne Muscular Dystrophy (DMD) Sales Sites, Area Served, Product Type
3.6 Drugs for Duchenne Muscular Dystrophy (DMD) Market Competitive Situation and Trends
3.6.1 Drugs for Duchenne Muscular Dystrophy (DMD) Market Concentration Rate
3.6.2 Global 5 and 10 Largest Drugs for Duchenne Muscular Dystrophy (DMD) Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Chain Analysis
4.1 Drugs for Duchenne Muscular Dystrophy (DMD) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Drugs for Duchenne Muscular Dystrophy (DMD) Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Drugs for Duchenne Muscular Dystrophy (DMD) Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2019-2025)
6.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Market Share by Type (2019-2025)
6.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Price by Type (2019-2025)
7 Drugs for Duchenne Muscular Dystrophy (DMD) Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Sales by Application (2019-2025)
7.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Application (2019-2025)
7.4 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Growth Rate by Application (2019-2025)
8 Drugs for Duchenne Muscular Dystrophy (DMD) Market Consumption by Region
8.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.1.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region
8.2 North America
8.2.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Drugs for Duchenne Muscular Dystrophy (DMD) Market Production by Region
9.1 Global Production of Drugs for Duchenne Muscular Dystrophy (DMD) by Region (2019-2025)
9.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Region (2019-2025)
9.3 Global Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Drugs for Duchenne Muscular Dystrophy (DMD) Production
9.4.1 North America Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2019-2025)
9.4.2 North America Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production
9.5.1 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2019-2025)
9.5.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production (2019-2025)
9.6.1 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2019-2025)
9.6.2 Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Drugs for Duchenne Muscular Dystrophy (DMD) Production (2019-2025)
9.7.1 China Drugs for Duchenne Muscular Dystrophy (DMD) Production Growth Rate (2019-2025)
9.7.2 China Drugs for Duchenne Muscular Dystrophy (DMD) Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Sarepta Therapeutics
10.1.1 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
10.1.2 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.1.3 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.1.4 Sarepta Therapeutics Business Overview
10.1.5 Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) SWOT Analysis
10.1.6 Sarepta Therapeutics Recent Developments
10.2 PTC Therapeutics
10.2.1 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
10.2.2 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.2.3 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.2.4 PTC Therapeutics Business Overview
10.2.5 PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) SWOT Analysis
10.2.6 PTC Therapeutics Recent Developments
10.3 Pfizer
10.3.1 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
10.3.2 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.3.3 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.3.4 Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) SWOT Analysis
10.3.5 Pfizer Business Overview
10.3.6 Pfizer Recent Developments
10.4 Bristol-Myers Squibb
10.4.1 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
10.4.2 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.4.3 Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.4.4 Bristol-Myers Squibb Business Overview
10.4.5 Bristol-Myers Squibb Recent Developments
10.5 Italfarmaco
10.5.1 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
10.5.2 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.5.3 Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.5.4 Italfarmaco Business Overview
10.5.5 Italfarmaco Recent Developments
10.6 Santhera Pharmaceuticals
10.6.1 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
10.6.2 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.6.3 Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.6.4 Santhera Pharmaceuticals Business Overview
10.6.5 Santhera Pharmaceuticals Recent Developments
10.7 WaVe life Science
10.7.1 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
10.7.2 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
10.7.3 WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Market Performance
10.7.4 WaVe life Science Business Overview
10.7.5 WaVe life Science Recent Developments
11 Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Region
11.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast
11.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country
11.2.3 Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Region
11.2.4 South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Drugs for Duchenne Muscular Dystrophy (DMD) by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2025-2032)
12.1.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2025-2032)
12.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Forecast by Application (2025-2032)
12.2.1 Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) Forecast by Application
12.2.2 Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Comparison by Region (M USD)
Table 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Manufacturers (2019-2025)
Table 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Duchenne Muscular Dystrophy (DMD) as of 2022)
Table 10. Global Market Drugs for Duchenne Muscular Dystrophy (DMD) Average Price (USD/MT) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Drugs for Duchenne Muscular Dystrophy (DMD) Sales Sites and Area Served
Table 12. Manufacturers Drugs for Duchenne Muscular Dystrophy (DMD) Product Type
Table 13. Global Drugs for Duchenne Muscular Dystrophy (DMD) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Drugs for Duchenne Muscular Dystrophy (DMD)
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Drugs for Duchenne Muscular Dystrophy (DMD) Market Challenges
Table 22. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Type (K MT)
Table 23. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Type (M USD)
Table 24. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Type (2019-2025)
Table 25. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Type (2019-2025)
Table 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) by Type (2019-2025)
Table 27. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Share by Type (2019-2025)
Table 28. Global Drugs for Duchenne Muscular Dystrophy (DMD) Price (USD/MT) by Type (2019-2025)
Table 29. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) by Application
Table 30. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Application
Table 31. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Application (2019-2025) & (K MT)
Table 32. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application (2019-2025)
Table 33. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Application (2019-2025) & (M USD)
Table 34. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2019-2025)
Table 35. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Growth Rate by Application (2019-2025)
Table 36. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region (2019-2025) & (K MT)
Table 37. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region (2019-2025)
Table 38. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2019-2025) & (K MT)
Table 39. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2019-2025) & (K MT)
Table 40. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region (2019-2025) & (K MT)
Table 41. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Country (2019-2025) & (K MT)
Table 42. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales by Region (2019-2025) & (K MT)
Table 43. Global Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) by Region (2019-2025)
Table 44. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Market Share by Region (2019-2025)
Table 46. Global Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 47. North America Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 48. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 49. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 50. China Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 51. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
Table 52. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 53. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 54. Sarepta Therapeutics Business Overview
Table 55. Sarepta Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) SWOT Analysis
Table 56. Sarepta Therapeutics Recent Developments
Table 57. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
Table 58. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 59. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 60. PTC Therapeutics Business Overview
Table 61. PTC Therapeutics Drugs for Duchenne Muscular Dystrophy (DMD) SWOT Analysis
Table 62. PTC Therapeutics Recent Developments
Table 63. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
Table 64. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 65. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 66. Pfizer Drugs for Duchenne Muscular Dystrophy (DMD) SWOT Analysis
Table 67. Pfizer Business Overview
Table 68. Pfizer Recent Developments
Table 69. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
Table 70. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 71. Bristol-Myers Squibb Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 72. Bristol-Myers Squibb Business Overview
Table 73. Bristol-Myers Squibb Recent Developments
Table 74. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
Table 75. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 76. Italfarmaco Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 77. Italfarmaco Business Overview
Table 78. Italfarmaco Recent Developments
Table 79. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
Table 80. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 81. Santhera Pharmaceuticals Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 82. Santhera Pharmaceuticals Business Overview
Table 83. Santhera Pharmaceuticals Recent Developments
Table 84. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Basic Information
Table 85. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Product Overview
Table 86. WaVe life Science Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 87. WaVe life Science Business Overview
Table 88. WaVe life Science Recent Developments
Table 89. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Region (2025-2032) & (K MT)
Table 90. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Region (2025-2032) & (M USD)
Table 91. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Country (2025-2032) & (K MT)
Table 92. North America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2025-2032) & (M USD)
Table 93. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Country (2025-2032) & (K MT)
Table 94. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2025-2032) & (M USD)
Table 95. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Region (2025-2032) & (K MT)
Table 96. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Region (2025-2032) & (M USD)
Table 97. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Country (2025-2032) & (K MT)
Table 98. South America Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2025-2032) & (M USD)
Table 99. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Consumption Forecast by Country (2025-2032) & (Units)
Table 100. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Country (2025-2032) & (M USD)
Table 101. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Type (2025-2032) & (K MT)
Table 102. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Type (2025-2032) & (M USD)
Table 103. Global Drugs for Duchenne Muscular Dystrophy (DMD) Price Forecast by Type (2025-2032) & (USD/MT)
Table 104. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) Forecast by Application (2025-2032)
Table 105. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Drugs for Duchenne Muscular Dystrophy (DMD)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD), 2019-2032
Figure 5. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size (M USD) (2019-2032)
Figure 6. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Drugs for Duchenne Muscular Dystrophy (DMD) Market Size by Country (M USD)
Figure 11. Drugs for Duchenne Muscular Dystrophy (DMD) Sales Share by Manufacturers in 2023
Figure 12. Global Drugs for Duchenne Muscular Dystrophy (DMD) Revenue Share by Manufacturers in 2023
Figure 13. Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Drugs for Duchenne Muscular Dystrophy (DMD) Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Drugs for Duchenne Muscular Dystrophy (DMD) Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Type
Figure 18. Sales Market Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2019-2025)
Figure 19. Sales Market Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type in 2023
Figure 20. Market Size Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type (2019-2025)
Figure 21. Market Size Market Share of Drugs for Duchenne Muscular Dystrophy (DMD) by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application
Figure 24. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application (2019-2025)
Figure 25. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Application in 2023
Figure 26. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application (2019-2025)
Figure 27. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share by Application in 2023
Figure 28. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Growth Rate by Application (2019-2025)
Figure 29. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region (2019-2025)
Figure 30. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 31. North America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Country in 2023
Figure 32. U.S. Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 33. Canada Drugs for Duchenne Muscular Dystrophy (DMD) Sales (K MT) and Growth Rate (2019-2025)
Figure 34. Mexico Drugs for Duchenne Muscular Dystrophy (DMD) Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 36. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Country in 2023
Figure 37. Germany Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 38. France Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 39. U.K. Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 40. Italy Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 41. Russia Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 42. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region in 2023
Figure 44. China Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 45. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 46. South Korea Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 47. India Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 48. Southeast Asia Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 49. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (K MT)
Figure 50. South America Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Country in 2023
Figure 51. Brazil Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 52. Argentina Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 53. Columbia Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 54. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 57. UAE Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 58. Egypt Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 59. Nigeria Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 60. South Africa Drugs for Duchenne Muscular Dystrophy (DMD) Sales and Growth Rate (2019-2025) & (K MT)
Figure 61. Global Drugs for Duchenne Muscular Dystrophy (DMD) Production Market Share by Region (2019-2025)
Figure 62. North America Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2019-2025)
Figure 63. Europe Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2019-2025)
Figure 64. Japan Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2019-2025)
Figure 65. China Drugs for Duchenne Muscular Dystrophy (DMD) Production (K MT) Growth Rate (2019-2025)
Figure 66. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Type (2025-2032)
Figure 70. Global Drugs for Duchenne Muscular Dystrophy (DMD) Sales Forecast by Application (2025-2032)
Figure 71. Global Drugs for Duchenne Muscular Dystrophy (DMD) Market Share Forecast by Application (2025-2032)
